Short Interest in RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) Decreases By 73.1%

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) was the recipient of a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 22,000 shares, a drop of 73.1% from the March 31st total of 81,700 shares. Based on an average trading volume of 7,859,600 shares, the days-to-cover ratio is currently 0.0 days.

RespireRx Pharmaceuticals Stock Up 5.9 %

RespireRx Pharmaceuticals stock traded up $0.00 during trading hours on Friday, hitting $0.00. The stock had a trading volume of 3,727,442 shares, compared to its average volume of 12,020,596. The stock has a market cap of $697,212.00, a price-to-earnings ratio of -0.04 and a beta of 0.49. RespireRx Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $0.02.

About RespireRx Pharmaceuticals

RespireRx Pharmaceuticals Inc engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors.